Elevated levels of the free thyroid hormone T3 (fT3) and a higher fT3/fT4 ratio in early pregnancy may point to a greater risk of developing gestational diabetes (GDM), according to a recent US-based study.
Adding bevacizumab to platinum-based chemotherapy significantly improves progression-free survival (PFS) in patients with recurrent ovarian cancer who were previously treated with first-line bevacizumab, according to the MITO16B - MaNGO OV2B - ENGOT OV17* study presented at ASCO 2018.
Incorporating polygenic risk scores based on 18 SNPs (single nucleotide polymorphisms) into risk stratification for breast cancer will improve screening results, says an expert.
Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.
Hereditary breast and ovarian cancer (HBOC) syndrome, which is primarily caused by BRCA1 and BRCA2 mutations, make up 8 to 10 percent of all breast cancers, says a senior consultant.
Identification of BRCA mutation in ovarian cancer is vital because it allows better risk management and there is evidence that carriers may benefit from new treatment modalities, said Professor Woo Yin Ling, consultant gynaecological oncologist at the University of Malaya.
A high daily dose of vitamin D (4,000 IU/day) resulted in a reduction in vitamin D deficiency in pregnant women, coupled with a lower risk of preterm births and low birth weight in their newborns, according to a study presented at RCOG 2018.